Cardiovascular Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for cardiovascular dealmaking

Cardiovascular remains one of the most active and strategically important therapeutic areas for partnering, with deal structures varying widely across indications, modalities, and stages of development.

This report provides a comprehensive and structured analysis of 650+ cardiovascular collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cardiovascular deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by stage, asset type, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within cardiovascular partnerships.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark live transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data
What's included
650+ cardiovascular collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy, and technology)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for cardiovascular dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cardiovascular partnerships are structured, negotiated, and valued.

Product Code: CP2202

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

2.1. Introduction
2.2. Cardiovascular partnering over the years
2.3. Cardiovascular partnering by deal type
2.4. Cardiovascular partnering by industry sector
2.5. Cardiovascular partnering by stage of development
2.6. Cardiovascular partnering by technology type
2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 - Financial deal terms for cardiovascular partnering

3.1. Introduction
3.2. Disclosed financials terms for cardiovascular partnering
3.3. Cardiovascular partnering headline values
3.4. Cardiovascular deal upfront payments
3.5. Cardiovascular deal milestone payments
3.6. Cardiovascular royalty rates

Chapter 4 - Leading cardiovascular deals and dealmakers

4.1. Introduction
4.2. Most active in cardiovascular partnering
4.3. List of most active dealmakers in cardiovascular
4.4. Top cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory

5.1. Introduction
5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by cardiovascular therapeutic target
Deal directory
Deal directory - Cardiovascular deals by company A-Z
Deal directory - Cardiovascular deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cardiovascular partnering since 2016
Figure 2: Cardiovascular partnering by deal type since 2016
Figure 3: Cardiovascular partnering by industry sector since 2016
Figure 4: Cardiovascular partnering by stage of development since 2016
Figure 5: Cardiovascular partnering by technology type since 2016
Figure 6: Cardiovascular partnering by indication since 2016
Figure 7: Cardiovascular deals with a headline value
Figure 8: Cardiovascular deals with upfront payment values
Figure 9: Cardiovascular deals with milestone payment
Figure 10: Cardiovascular deals with royalty rates
Figure 11: Active cardiovascular dealmaking activity since 2016
Figure 12: Top cardiovascular deals by value since 2016